2020 American Transplant Congress
Comparison of Anti-Thymocyte Globulin and Alemtuzumab as Induction Therapy in Older Kidney Transplant Recipients
Rush University Medical Center, Chicago, IL
*Purpose: The purpose of this study is to evaluate the safety and efficacy of induction with either anti-thymocyte globulin (ATG) (total dose 5 mg/kg) or…2020 American Transplant Congress
Low-Dose Rabbit Antithymocyte Globulin Induction in Elderly Kidney Transplant Recipients at High Immunologic Risk is Safe and May Prevent Excess Rejection
1University of Colorado Hospital, Aurora, CO, 2University of Colorado School of Medicine, Aurora, CO
*Purpose: Patients aged ≥65 years are a growing segment of kidney transplant recipients (KTRs). Consensus on induction immunosuppression in this population is unclear given higher…2020 American Transplant Congress
Impact of Alemtuzumab Induction on Cardiac Allograft Vasculopathy in Orthotopic Heart Transplant Recipients
*Purpose: Cardiac allograft vasculopathy (CAV) is impacted by acute rejection and ultimately limits long-term survival of orthotopic heart transplant (OHT) recipients, thus there is interest…2020 American Transplant Congress
Pancreas Transplant in Patients Older Than 50: An Analysis of Outcomes and Immunosuppression
*Purpose: Pancreas transplant (PT) is the ideal therapy for many patients with diabetes and kidney failure. There are limited published data addressing the impact of…2020 American Transplant Congress
Thymoglobulin (ATG) Induction vs. Campath vs. Simulect in DCD Kidneys in UK; Induction Regimes Play a Role after All
*Purpose: Controlled DCD kidneys have increased dramatically in UK. They suffer from a higher rate of DGF and, often in UK, come from older donors…2020 American Transplant Congress
Safety Outcomes in Lower-Weight vs Higher-Weight Recipients of Fixed Dose Alemtuzumab for Kidney Transplant Induction
Ochsner Medical Center, New Orleans, LA
*Purpose: Alemtuzumab is a lymphocyte-depleting monoclonal antibody used for renal transplant induction, and is associated with significant leukopenia, increased infections and malignancy. Multiple dosing strategies…2020 American Transplant Congress
Ten Year Results of a Single Center Study of Rabbit Anti-Thymocyte Globulin Compared to Alemtuzumab Induction in Simultaneous Pancreas-Kidney Transplantation
Abdominal Transplant Surgery, Wake Forest Baptist Health, Winston Salem, NC
*Purpose: The study purpose was to analyze 10-year outcomes of depleting antibody induction agents in simultaneous pancreas-kidney transplant (SPKT) at a single center*Methods: From 2/02…2020 American Transplant Congress
Anti-Thymocyte Globulins Induced Immunomodulatory Effect and Increased Regulatory T Cell in a In Vitro Model of Allogeneic Cell Coculture
*Purpose: Two types of Anti-Thymocyte Globulins (ATG) are commonly used in renal transplantation (Thymoglobuline and Grafalon) and induce severe, dose-dependent and sometimes persistent CD4+ T…2019 American Transplant Congress
Antithymocyte Globulin is Associated with Mature T Cell Phenotypes and Decreased Risk of Non-EBV Infections in Transplanted Children
*Purpose: Depletional induction therapies are known to reduce the rate of acute rejection; yet data from the US Renal Data System have shown that use…2019 American Transplant Congress
Induction Therapy in Elderly Kidney Transplant Recipients with Low Immunological Risk
*Purpose: Thymoglobulin (ATG) and Basiliximab (BSX) lead to similar rejection rates in low immunological risk patients. ATG seems to be associated with infectious and malignancy…
- « Previous Page
- 1
- …
- 7
- 8
- 9
- 10
- 11
- …
- 31
- Next Page »